Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CVRx ( (CVRX) ) just unveiled an update.
On June 3, 2025, CVRx, Inc. held its annual meeting of stockholders where key decisions were made. The election of two Class I directors, Kevin Ballinger and Mitch Hill, was confirmed, and the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are pivotal for CVRx’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (CVRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.
Spark’s Take on CVRX Stock
According to Spark, TipRanks’ AI Analyst, CVRX is a Neutral.
CVRx’s stock score reflects solid revenue growth but is weighed down by profitability challenges and weak technical indicators. The earnings call provided a positive long-term outlook, but short-term obstacles like sales force realignment and seasonality remain. Valuation metrics indicate concerns about profitability, impacting the stock’s attractiveness.
To see Spark’s full report on CVRX stock, click here.
More about CVRx
CVRx, Inc. operates in the medical technology industry, focusing on developing innovative therapies for cardiovascular diseases. The company is known for its implantable devices that help manage chronic conditions, aiming to improve patient outcomes and quality of life.
Average Trading Volume: 419,910
Technical Sentiment Signal: Sell
Current Market Cap: $176.3M
For detailed information about CVRX stock, go to TipRanks’ Stock Analysis page.